Orchid Pharma Limited · NSE:ORCHPHARMA
Orchid Pharma — Q2 FY24 Earnings Presentation
12 slides from Orchid Pharma's earnings presentation, Nov 6, 2023
Slide 1: Investors Presentation Q2 FY24 cover letter
November 06, 2023 National Stock Exchange of India Limited, BSE Limited Exchange Plaza, Bandra Kurla Complex Phiroze Jeejeebhoy Towers, Bandra (E), Mumbai-400051 Dalal Street, Fort, Mumbai-400001 Symbol: ORCHPHARMA Scrip Code: 524372 Subject: Investors Presentation Q2 FY24 – Orchid Pharma Limited (“
Slide 2: Q2-FY24 Results
Q2-FY24 Results © Copyright OrchidPharma Ltd. All Rights Reserved 1
Slide 3: Safe Harbor
SAFE HARBOR FY2023 This presentation and the accompanying slides (the “Presentation”), which have been prepared by Orchid Pharma Ltd (the “Company’), have been prepared solely for information purposes and do not constitute any offer, recommendation or invitation to purchase or subscribe for any secu
Slide 4: Financial Highlights
Financial Highlights FY2023 (Rs/Crore)` Q2-2024 Q2-2023 Change % 6M-30th Sep’24 6M-30th Sep’23 Change % Sales 198.8 165.2 +20% 381.7 296.2 +29% Other Income 7.5 5.8 +29% 8.8 8.8 +0% COGS 122.4 100.3 234.4 170.1 Employee Exp 17.2 17.7 -3% 33.4 32.3 +3% Other Exp 35.5 29.4 68.0 63.5 EBITDA 31.2 18.9 +
Slide 5: Status of Term Loans
FY2023 Status of Term Loans Your Company has fully paid all the term loan taken from Banks now. © Copyright OrchidPharma Ltd. All Rights Reserved 4
Slide 6: Total Income
FY2023 TOTAL INCOME 800 700 685 600 566 500 392 400 305 300 200 100 0 FY22 FY23 HY1-FY23 HY1-FY24 © Copyright OrchidPharma Ltd. All Rights Reserved 5
Slide 7: EBITDA
FY2023 EBITDA 120 16% 15% 103 14% 14% 100 13% 12% 12% 80 10% 66 60 56 8% 39 6% 40 4% 20 2% 0 0% FY22 FY23 HY1-FY23 HY1-FY24 EBITDA %age Income © Copyright OrchidPharma Ltd. All Rights Reserved 6
Slide 8: PAT
FY2023 PAT 40 10% 31 30 8% 8% 20 16 6% 10 4% 0 2% 2% -10 FY22 FY23 HY1-FY23 HY1-FY24 0% -20 -17 -2% -30 -4% -40 -6% -6% -50 -8% -60 -53-9% -10% PAT %age Income © Copyright OrchidPharma Ltd. All Rights Reserved 7
Slide 9: Expense Breakup
FY2023 EXPENSE BREAKUP 140 132 35% 125 31% 120 30% 33% 29% 100 26% 25% 80 20% 65 68 64 60 60 15% 40 32 33 10% 20 5% 0 0% FY22 FY23 HY1-FY23 HY1-FY24 Employee Expense Other Expenses %age Income © Copyright OrchidPharma Ltd. All Rights Reserved 8
Slide 10: Leverage
FY2023 LEVERAGE 40% 36% 35% 30% 29% 25% 24% 21% 21% 20% 15% 12% 12% 10% 8% 5% 0% FY22 FY23 HY1-FY23 HY1-FY24 %increase in total Income %increase/dec in expenses © Copyright OrchidPharma Ltd. All Rights Reserved 9
Slide 11: Summary Results
SUMMARY RESULTS FY2023 Rs. In Cr. Particulars FY 2022-23 FY 2021-22 HY1-FY23 HY1-FY24 Net Sales/Income from Operations 666 557 296 382 Other Income 19 9 9 10 Total Income 685 566 305 392 Raw Material Cost 385 314 170 234 Employee benefit expenses 65 60 32 33 Finance Costs 32 32 17 9 Depreciation & a
Slide 12: Thank You!
Thank You! © Copyright OrchidPharma Ltd. All Rights Reserved 11